Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study.
José Enrique Alés-MartínezJudith BalmañaPedro Sánchez-RoviraFrancisco Javier Salvador BofillJose Ángel García SáenzIsabel PimentelSerafín MoralesMaría Fernández-AbadAinhara Lahuerta MartínezNeus FerrerPilar ZamoraBegoña BermejoTamara Díaz-RedondoMaría Helena López-CeballosMaría GalánJhudit Pérez-EscuredoLaura CalabuigMiguel SampayoJosé Manuel Pérez-GarciaJavier CortésAntonio Llombart-CussacPublished in: Breast (Edinburgh, Scotland) (2024)
This study suggests that the combination of olaparib plus trastuzumab may be effective and safe in pre-treated patients with HER2-positive gBRCAm ABC. This ABC patient population should be further studied and not be pre-emptively excluded from clinical trials of targeted therapy for BRCA1/2-driven cancers.